| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pathology [B. K. A. R., R. E. M., D. D. B., S. H. B.], Community and Family Medicine, Division of Biometry [J. E. H.], Pediatrics [H. S. F.], and Surgery [A. H. F.], and Preuss Laboratory for Brain Tumor Research [H. S. F., D. D. B.], Duke University Medical Center, Durham, North Carolina 27710
Glial tumors of all grades and histological types from 72 adults and 48 children were analyzed for mutations of the TP53 gene, loss of heterozygosity (LOH) for 17p, and accumulation of TP53 protein to determine whether the incidence and type of TP53 alterations differ among tumors of different histological type and between tumors from adults and children. These tumors were also evaluated for LOH for chromosome 10 and for amplification of the epidermal growth factor receptor, C-MYC, N-MYC, GLI, platelet-derived growth factor receptor-
, and murine double minute 2 genes to determine the patterns of molecular alterations involved in the progression of these neoplasms. Seventeen of the 120 tumors contained mutations of the TP53 gene. One of the tumors with TP53 gene mutation was from one of the 48 patients less than 18 years of age. Twelve of the 17 tumors with mutations occurred among the 27 patients in the 18–45-year age group, while 4 tumors with mutations were among the 45 patients more than 45 years old. There was also an increased incidence of TP53 mutation in patients with anaplastic astrocytoma histology. However, no significant association between presence of TP53 mutation and patient survival was observed. These studies demonstrate that TP53 gene mutations are a common mechanism for glial cell neoplasms in the 18–45-year age group but are unrelated to progression and advanced histological grade. LOH for chromosome 10 and gene amplification, however, occurring in 82 and 40%, respectively, of glioblastoma multiforme, whether seen alone or along with TP53 gene alterations, are related to advanced histological grade of the tumor. In childhood gliomas, in contrast, TP53 gene alterations, LOH for 17p and 10q, and gene amplification are uncommon in tumors of all grades, suggesting that presently unknown mechanisms are responsible for the genesis and progression of these tumors.
1 This work was supported by NIH Grant CA 43722.
2 To whom requests for reprints should be addressed, at Box 3712, Department of Pathology, Duke University Medical Center, Durham, NC 27710.
Received 9/15/93. Accepted 12/28/93.
This article has been cited by other articles:
|
|
 |
|
  T. Hide, T. Takezaki, Y. Nakatani, H. Nakamura, J.-i. Kuratsu, and T. Kondo Sox11 Prevents Tumorigenesis of Glioma-Initiating Cells by Inducing Neuronal Differentiation Cancer Res., October 15, 2009; 69(20): 7953 - 7959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Suri, P. Das, A. Jain, M. C. Sharma, S. A. Borkar, A. Suri, D. Gupta, and C. Sarkar Pediatric glioblastomas: A histopathological and molecular genetic study Neuro-oncol, January 1, 2009; 11(3): 274 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Hawes, J. D. Nerva, and K. M. Reilly Novel Dual-Reporter Preclinical Screen for Antiastrocytoma Agents Identifies Cytostatic and Cytotoxic Compounds J Biomol Screen, September 1, 2008; 13(8): 795 - 803. [Abstract] [PDF]
|
|
|
|
 |
|
 D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kim, H.-H. L. Hong, Y. Lachat, N. P. Clayton, T. R. Devereux, R. L. Melnick, M. E. Hegi, and R. C. Sills Genetic Alterations in Brain Tumors Following 1,3-Butadiene Exposure in B6C3F1 Mice Toxicol Pathol, April 1, 2005; 33(3): 307 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V P Collins Brain tumours: classification and genes J. Neurol. Neurosurg. Psychiatry, June 1, 2004; 75(suppl_2): ii2 - ii11. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Backlund, B. R. Nilsson, H. M. Goike, E. E. Schmidt, L. Liu, K. Ichimura, and V. P. Collins Short Postoperative Survival for Glioblastoma Patients with a Dysfunctional Rb1 Pathway in Combination with No Wild-type PTEN Clin. Cancer Res., September 15, 2003; 9(11): 4151 - 4158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. F. Pollack, S. D. Finkelstein, J. Woods, J. Burnham, E. J. Holmes, R. L. Hamilton, A. J. Yates, J. M. Boyett, J. L. Finlay, R. Sposto, et al. Expression of p53 and Prognosis in Children with Malignant Gliomas N. Engl. J. Med., February 7, 2002; 346(6): 420 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. F. Pollack, S. D. Finkelstein, J. Burnham, E. J. Holmes, R. L. Hamilton, A. J. Yates, J. L. Finlay, and R. Sposto Age and TP53 Mutation Frequency in Childhood Malignant Gliomas: Results in a Multi-institutional Cohort Cancer Res., October 1, 2001; 61(20): 7404 - 7407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Louis, E. C. Holland, and J. G. Cairncross Glioma Classification : A Molecular Reappraisal Am. J. Pathol., September 1, 2001; 159(3): 779 - 786. [Full Text] [PDF]
|
|
|
|
|
|
C. H. Rickert, R. Strater, P. Kaatsch, H. Wassmann, H. Jurgens, B. Dockhorn-Dworniczak, and W. Paulus Pediatric High-Grade Astrocytomas Show Chromosomal Imbalances Distinct from Adult Cases Am. J. Pathol., April 1, 2001; 158(4): 1525 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Simmons, K. R. Lamborn, M. Takahashi, P. Chen, M. A. Israel, M. S. Berger, T. Godfrey, J. Nigro, M. Prados, S. Chang, et al. Analysis of Complex Relationships between Age, p53, Epidermal Growth Factor Receptor, and Survival in Glioblastoma Patients Cancer Res., February 1, 2001; 61(3): 1122 - 1128. [Abstract] [Full Text]
|
|
|
|
|
|
L. J. Ostruszka and D. S. Shewach The Role of Cell Cycle Progression in Radiosensitization by 2',2'-Difluoro-2'-deoxycytidine Cancer Res., November 1, 2000; 60(21): 6080 - 6088. [Abstract] [Full Text]
|
|
|
|
|
|
H. Kato, S. Kato, T. Kumabe, Y. Sonoda, T. Yoshimoto, S. Kato, S.-Y. Han, T. Suzuki, H. Shibata, R. Kanamaru, et al. Functional Evaluation of p53 and PTEN Gene Mutations in Gliomas Clin. Cancer Res., October 1, 2000; 6(10): 3937 - 3943. [Abstract] [Full Text]
|
|
|
|
|
|
R. N. Wiltshire, B.K. A. Rasheed, H. S. Friedman, A. H. Friedman, and S. H. Bigner Comparative genetic patterns of glioblastoma multiforme: Potential diagnostic tool for tumor classification Neuro-oncol, July 1, 2000; 2(3): 164 - 173. [Abstract] [PDF]
|
|
|
|
|
|
E. C. Holland A Mouse Model for Glioma: Biology, Pathology, and Therapeutic Opportunities Toxicol Pathol, January 1, 2000; 28(1): 171 - 177. [Abstract] [PDF]
|
|
|
|
|
|
C. Raffel, L. Frederick, J. R. O'Fallon, P. Atherton-Skaff, A. Perry, R. B. Jenkins, and C. D. James Analysis of Oncogene and Tumor Suppressor Gene Alterations in Pediatric Malignant Astrocytomas Reveals Reduced Survival for Patients with PTEN Mutations Clin. Cancer Res., December 1, 1999; 5(12): 4085 - 4090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Sills, J. R. Hailey, J. Neal, G. A. Boorman, J. K. Haseman, and R. L. Melnick Examination of Low-Incidence Brain Tumor Responses in F344 Rats Following Chemical Exposures in National Toxicology Program Carcinogenicity Studies Toxicol Pathol, September 1, 1999; 27(5): 589 - 599. [Abstract] [PDF]
|
|
|
|
|
|
S. H. Bigner, M. R. Matthews, B. K. A. Rasheed, R. N. Wiltshire, H. S. Friedman, A. H. Friedman, T. T. Stenzel, D. M. Dawes, R. E. McLendon, and D. D. Bigner Molecular Genetic Aspects of Oligodendrogliomas Including Analysis by Comparative Genomic Hybridization Am. J. Pathol., August 1, 1999; 155(2): 375 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bredel, I. F. Pollack, R. L. Hamilton, and C. D. James Epidermal Growth Factor Receptor Expression and Gene Amplification in High-Grade Non-Brainstem Gliomas of Childhood Clin. Cancer Res., July 1, 1999; 5(7): 1786 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kamijo, S. Bodner, E. van de Kamp, D. H. Randle, and C. J. Sherr Tumor Spectrum in ARF-deficient Mice Cancer Res., May 1, 1999; 59(9): 2217 - 2222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nozaki, M. Tada, H. Kobayashi, C.-L. Zhang, Y. Sawamura, H. Abe, N. Ishii, and E. G. Van Meir Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression Neuro-oncol, April 1, 1999; 1(2): 124 - 137. [Abstract] [PDF]
|
|
|
|
|
|
P. Kleihues and H. Ohgaki Primary and secondary glioblastomas: From concept to clinical diagnosis Neuro-oncol, January 1, 1999; 1(1): 44 - 51. [Abstract] [PDF]
|
|
|
|
 |
|
 E. C. Holland, W. P. Hively, R. A. DePinho, and H. E. Varmus A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice Genes & Dev., December 1, 1998; 12(23): 3675 - 3685. [Abstract] [Full Text]
|
|
|
|
 |
|
 H.-K. G. Shu, M. M. Kim, P. Chen, F. Furman, C. M. Julin, and M. A. Israel The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21BAX expression PNAS, November 24, 1998; 95(24): 14453 - 14458. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
